STOCK MARKET BSE NSE

NII's potential COVID-19 vaccine shows encouraging results in immunogenicity study on mice

The NII, an institute under the Department of Biotechnology, has started the process of developing protein-based vaccine candidates against the coronavirus.

Published: 12th September 2020 08:31 AM  |   Last Updated: 12th September 2020 08:31 AM   |  A+A-

Vaccine

Image for representational purpose

By PTI

NEW DELHI: An immunogenicity study conducted on mice for the coronavirus vaccine candidate being developed by the National Institute of Immunology has shown encouraging results, NII director Amulya Panda said on Friday.

The NII, an institute under the Department of Biotechnology, has started the process of developing protein-based vaccine candidates against the coronavirus.

"The preliminary results of the immunogenicity study trials done on mice have shown positive results. We found it to be highly immunogenic, neutralising and it produced antibodies," Panda said.

The NII's vaccine candidate is one of the many being developed indigenously.

The immunogenicity study trial on mice was conducted in July.

Panda said more tests need to be done on mice on a larger scale now and it is expected to start next week.

"We are also working to see how good it is at neutralising (the coronavirus) in humans," he said.

"Further, we plan to do it (test) in monkeys to get more solid data," he said, adding that clearances have to be taken to conduct such tests on primates. In the past, the NII had developed a vaccine against leprosy which is already in the market. It is also working on a cancer vaccine which is in phase 3 trial."

Panda said the aim is to make a cheaper vaccine which can be made available to the masses.

Two other indigenous vaccine candidates -- Zydus Cadila and Bharat Biotech -- have finished phase 1 of human trials and have moved to phase 2.

The Serum Institute of India (SII) on Thursday announced that it has paused clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country Earlier this week, pharma giant AstraZeneca had said it had paused the trials because of 'an unexplained illness' in a participant in the study.

The Drugs Controller General of India had issued a show-cause notice to the SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate for COVID-19 in other countries and also for not submitting a casualty analysis of the "reported serious adverse events".

More from Nation.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp